Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · IEX Real-Time Price · USD
1.045
+0.015 (1.46%)
Jul 22, 2024, 10:15 AM EDT - Market open
Gossamer Bio Employees
Gossamer Bio had 135 employees as of December 31, 2023. The number of employees decreased by 43 or -24.16% compared to the previous year.
Employees
135
Change (1Y)
-43
Growth (1Y)
-24.16%
Revenue / Employee
n/a
Profits / Employee
-$1,278,370
Market Cap
240.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
2seventy bio | 274 |
Cibus | 183 |
NeuroPace | 171 |
Mersana Therapeutics | 123 |
Semler Scientific | 92 |
Design Therapeutics | 58 |
Rezolute | 51 |
Cybin | 50 |
GOSS News
- 26 days ago - Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says - Benzinga
- 6 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference - Business Wire
- 2 months ago - Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - Reuters
- 2 months ago - Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications - Business Wire
- 2 months ago - Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine - Business Wire
- 4 months ago - Gossamer Bio Announces Appointment of Steven D. Nathan, M.D. - Business Wire